Search

Displaying results 3371 - 3380 of 8700 in total
  1. Drug

    Oxybuprocaine

    go.drugbank.com/drugs/DB00892
    ApprovedInvestigational

    Oxybuprocaine (also known as Benoxinate) is a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its perm...

    Categories: Anesthetics for Topical UseProducts: Benoxinat 1% - Lösung zur Anästhesie in der Oto-Rhino-Laryngologie
  2. Drug

    Gotistobart

    go.drugbank.com/drugs/DB19100
    Investigational

    Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).

  3. Drug

    Arachidonic Acid

    go.drugbank.com/drugs/DB04557
    ApprovedInvestigationalWithdrawn

    An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides.

    Mixtures: NEUROGAIN PB VEGICAP CAPSULE 500MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  4. Drug

    Naftifine

    go.drugbank.com/drugs/DB00735
    Approved

    Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  5. Drug

    PF-04418948

    go.drugbank.com/drugs/DB12024
    Investigational

    Pf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers).

  6. Drug

    Disulfiram

    go.drugbank.com/drugs/DB00822
    ApprovedInvestigational

    A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. … Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

  8. Drug

    Procaterol

    go.drugbank.com/drugs/DB01366
    ApprovedWithdrawn

    A long-acting beta-2-adrenergic receptor agonist. It is a potent bronchodilator that may be administered orally or by aerosol inhalation.

    Categories: Adrenergics for Systemic Use, Drugs for Obstructive Airway Diseases
  9. Drug

    Virus Specific T-Cell

    go.drugbank.com/drugs/DB15735
    Investigational

    Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. … Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation.

  10. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.